CoChat

Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials

Open access
Sim, Kang, Lau, Wai Keat, Sim, Jordan, Sum, Min Yi, Baldessarini, Ross J. · 2016 · International Journal of Neuropsychopharmacology

The DOI matches its Crossref record; 129 of the 137 references it cites were found in a registry or an index; 14 of the 57 sources its claims cite were checked for support.

Abstract

BACKGROUND: Findings of substantial remaining morbidity in treated major depressive disorder (MDD) led us to review controlled trials of treatments aimed at preventing early relapses or later recurrences in adults diagnosed with MDD to summarize available data and to guide further research. METHODS: Reports (n = 97) were identified through systematic, computerized literature searching up to February 2015. Treatment versus control outcomes were summarized by random-effects meta-analyses. RESULTS: In 45 reports of 72 trials (n = 14 450 subjects) lasting 33.4 weeks, antidepressants were more effective than placebos in preventing relapses (response rates [RR] = 1.90, confidence interval [CI]: 1.73-2.08; NNT = 4.4; p < 0.0001). In 35 reports of 37 trials (n = 7253) lasting 27.0 months, antidepressants were effective in preventing recurrences (RR = 2.03, CI 1.80-2.28; NNT = 3.8; p < 0.0001), with minor differences among drug types. In 17 reports of 22 trials (n = 1 969) lasting 23.7 months, psychosocial interventions yielded inconsistent or inconclusive results. CONCLUSIONS: Despite evidence of the efficacy of drug treatment compared to placebos or other controls, the findings further underscore the substantial, unresolved morbidity in treated MDD patients and strongly encourage further evaluations of specific, improved individual and combination therapies (pharmacological and psychological) conducted over longer times, as well as identifying clinical predictors of positive or unfavorable responses and of intolerability of long-term treatments in MDD.

Overview

CoChat Summary

TL;DR

This systematic review and meta-analysis found that antidepressants significantly reduce relapse and recurrence in adults with major depressive disorder compared with placebo, with long-term maintenance treatment showing the largest pooled effect. Psychosocial interventions yielded inconsistent and generally weaker evidence, though some benefit appeared in patients with multiple prior episodes.

Key findings

  • In 45 reports of 72 continuation trials (n = 14,450; mean 8.35 months), antidepressants were more effective than placebo in preventing relapse: RR = 1.90 (95% CI 1.73–2.08), NNT = 4.4 (3.8–5.2), p < 0.0001; relapse risk averaged 23.3% with continued antidepressant vs 49.4% after discontinuation.
  • In 35 reports of 37 long-term trials (n = 7,253; mean 26.8 months), antidepressants were effective in preventing recurrence: RR = 2.03 (95% CI 1.80–2.28), NNT = 3.8 (3.3–4.6), p < 0.0001; 32/37 (86.5%) trials showed significant superiority of active drug over control.
  • In 17 reports of 22 psychosocial trials (n = 1,969; mean 23.7 months), pooled RR = 1.39 (95% CI 1.13–1.70), NNT = 6.0 (3.8–14), p = 0.002, but 11/22 (50.0%) comparisons were nonsignificant; benefit was greater in patients with high prior recurrences (RR = 1.63, 95% CI 1.04–2.57) than low prior recurrences (RR = 0.80, 95% CI 0.58–1.09).
  • Meta-regression found longer initial treatment before randomization was associated with larger drug–placebo contrast in continuation trials (β = +0.048, CI 0.024–0.073, p < 0.001), and longer long-term treatment duration was associated with larger drug–placebo contrast in maintenance trials (β = +0.104, CI 0.044–0.163, p < 0.001).

Methods

  • Systematic review and random-effects meta-analysis of controlled trials identified through computerized searches of PubMed/Medline, Scieverse, SciDirect, and Web-of-Science up to February 2015; 803 reports screened, 146 reviewed in detail, and 97 reports included.
  • Inclusion required adults with major depressive disorder, English-language reports, and examination of relapse or recurrence with pharmacological or non-pharmacological treatment; exclusions were bipolar depression, seasonal depression, juvenile depression, and studies only of adverse events or costs.
  • Two investigators independently extracted data; analyses computed relative response rates (RRs), rate differences, and number-needed-to-treat (NNT), with meta-regression testing covariates including trial year, size, age, sex proportion, prior episodes, initial treatment weeks, trial duration, and antidepressant type.

Limitations

  • Stated by the paper: few well-designed non-pharmacological or combination-treatment studies; follow-up periods ranged from several months to five years (average up to 2 years), with actual times to new episodes usually not reported; many trials used “enriched” designs requiring short-term response, limiting generalizability; many trials discontinued active treatment in barely recovered patients, possibly contributing to inferior placebo outcomes; juvenile and mainly geriatric depression were excluded; some placebo arms were reused in multi-arm trials, though sensitivity analyses showed minor effects; and many studies lacked clinical details on prior episodes, subjective wellness, functioning, and predictors of tolerability or response.
  • Evident from the text: psychosocial trials were heterogeneous and half of comparisons were nonsignificant, making conclusions about psychosocial maintenance treatment less secure than those for antidepressants.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1093/ijnp/pyv076

Cites

129 of 129 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Flow chart of study selection process: 803 reports screened, 146 reviewed in detail, and 97 included for analysis, following Preferred Reporting Items for Systematic Reviews and Meta-Analyses recommendations (http://www.prisma-statement.org/statement.htm).
Figure 1. Flow chart of study selection process: 803 reports screened, 146 reviewed in detail, and 97 included for analysis, following Preferred Reporting Items for Systematic Reviews and Meta-Analyses recommendations (http://www.prisma-statement.org/statement.htm).CC BY-NC · PubMed Central
Figure 2. Findings from random-effects meta-analysis of 37 controlled, long-term trials (>12 months) of antidepressants vs. placebos in major depression. The pooled ratio (RR) of recurrence risk with placebo vs. antidepressants, of 2.03 [CI: 1.80-2.28]) is highly significant (z-score = 11.7, p < 0.0001).
Figure 2. Findings from random-effects meta-analysis of 37 controlled, long-term trials (>12 months) of antidepressants vs. placebos in major depression. The pooled ratio (RR) of recurrence risk with placebo vs. antidepressants, of 2.03 [CI: 1.80-2.28]) is highly significant (z-score = 11.7, p < 0.0001).CC BY-NC · PubMed Central

Verification

Claims the paper makes

10 Valid · 1 Not valid · 20 Not checked · 55 Own results and interpretations

51 more claims · 3 with their cited sources checked

Create a free account to see all 86 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 12
  • It may state two separate claims as one. 22

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

8 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Statistics recomputed

Every reported test result, recomputed from its test statistic and degrees of freedom. A result shows as not adding up only once an independent check has confirmed it.

  • Consistentz = 11.7reported p < .0001 · recomputed p < .001

    “(z=11.7, p < .0001”

  • Consistentz = 11.7reported p < .0001 · recomputed p < .001

    “z = 11.7, p < .0001”

  • Consistentz = 3.15reported p = .002 · recomputed p = .002

    “(z = 3.15, p = .002”

  • Consistentz = 2.14reported p = .03 · recomputed p = .032

    “z = 2.14, p = .03”

  • Consistentz = 1.41reported p = .16 · recomputed p = .159

    “z = 1.41, p = .16”

5 of 7 · the rest aren’t loaded

2 more recomputed tests

Create a free account to see every test the Stats check recomputed.

See all tests — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

5 of 5

Citations

Cites

Show all 129 references

Research works printed but not linked: 3

  1. Georgotas, 1985, Affective disorders: pharmacotherapy, Compr Psychiatry, 4, 821
  2. 10.1176/appi.ajp.131.2.186 · doi:10.1176/appi.ajp.131.2.186
  3. Lendresse, 1985, Traitement prolongé par nomifensine 75mg dans les états dépressifs neurotiques et reactionnels, Psychiatrie Francaise, 16, 156

Cited by

See all 219

Metadata

Authors
Sim, K., Lau, W. K., Sim, J., Sum, M. Y., & Baldessarini, R. J.
Affiliations
Harvard University (US)
Corresponding author
Sim, Kang
Venue
International Journal of Neuropsychopharmacology
Published
2015-07-07
Volume
19
Issue
2
Pages
pyv076
ISSN
  • 1461-1457 (ISSN-L)
  • 1469-5111
OpenAlex
W1913659607
Cited by
218
References
137
Citations by year
2026: 8 · 2025: 19 · 2024: 22 · 2023: 20 · 2022: 23 · 2021: 38 · 2020: 34 · 2019: 20 · 2018: 10 · 2017: 10 · 2016: 12 · 2015: 1
FWCI
1.38
Type
journal article
Language
en
Open access
Locations
  • The International Journal of Neuropsychopharmacology (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
  • HighWire Press Open Archive (submittedVersion)
Funders
  • Bruce J. Anderson Foundation
  • Forskningsrådet om Hälsa, Arbetsliv och Välfärd
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
  • Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
Keywords
major depressive disorder, relapse prevention, recurrence prevention, antidepressants, psychosocial interventions, long-term treatment, predictors of treatment response, residual depressive symptoms
MeSH terms
Antidepressive Agents, Combined Modality Therapy, Major Depressive Disorder, Humans, Psychotherapy, Recurrence, Controlled Clinical Trials as Topic, Secondary Prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials. https://app.cochat.ai/papers/10.1093/ijnp/pyv076
The paper
Sim, K., Lau, W. K., Sim, J., Sum, M. Y., & Baldessarini, R. J. (2016). Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials. International Journal of Neuropsychopharmacology. https://doi.org/10.1093/ijnp/pyv076

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.